A Study of RO5045337 [RG7112] in Patients With Hematologic Neoplasms.

Inclusion Criteria: * Adult patients, \>=18 years of age * Acute myeloid leukemia, acute lymphocytic leukemia, chronic myelogenous leukemia in blast phase, refractory chronic lymphocytic leukemia/small cell lymphocytic lymphoma * Relapsed or refractory to approved therapies, or no viable alternative therapy available * ECOG performance status of 0-2 Exclusion Criteria: * Patients receiving any other agent or therapy to treat their malignancy * Pre-existing gastrointestinal disorders which may interfere with absorption of drugs * Clinically significant cardiovascular disease * Pregnant or lactating women * HIV-positive patients receiving combination antiretroviral therapy * Amendment J and onward for patients in the food effect evaluation and for all subsequent patients if dosing with a high fat/high calorie meal is found to be optimal: Patients with allergies to any ingredient in the defined liquid supplement and/or inability to tolerate a high fat/high calorie meal twice daily on scheduled RO5045337 dosing days